Switch theme
Sign up to access all valuation multiples
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
2015
145
LTM Revenue $78.3M
LTM EBITDA -$92.8M
$198M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Gossamer Bio has a last 12-month revenue (LTM) of $78.3M and a last 12-month EBITDA of -$92.8M.
In the most recent fiscal year, Gossamer Bio achieved revenue of $115M and an EBITDA of -$40.0M.
Gossamer Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Gossamer Bio valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $78.3M | XXX | $115M | XXX | XXX | XXX |
| Gross Profit | $76.2M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 97% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$92.8M | XXX | -$40.0M | XXX | XXX | XXX |
| EBITDA Margin | -119% | XXX | -35% | XXX | XXX | XXX |
| EBIT | -$101M | XXX | -$59.9M | XXX | XXX | XXX |
| EBIT Margin | -129% | XXX | -52% | XXX | XXX | XXX |
| Net Profit | -$99.6M | XXX | -$56.5M | XXX | XXX | XXX |
| Net Margin | -127% | XXX | -49% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $151M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Gossamer Bio's stock price is $1.
Gossamer Bio has current market cap of $253M, and EV of $198M.
See Gossamer Bio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $198M | $253M | XXX | XXX | XXX | XXX | $-0.42 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Gossamer Bio has market cap of $253M and EV of $198M.
Gossamer Bio's trades at 1.7x EV/Revenue multiple, and -5.0x EV/EBITDA.
Equity research analysts estimate Gossamer Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Gossamer Bio has a P/E ratio of -2.5x.
See valuation multiples for Gossamer Bio and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $253M | XXX | $253M | XXX | XXX | XXX |
| EV (current) | $198M | XXX | $198M | XXX | XXX | XXX |
| EV/Revenue | 2.5x | XXX | 1.7x | XXX | XXX | XXX |
| EV/EBITDA | -2.1x | XXX | -5.0x | XXX | XXX | XXX |
| EV/EBIT | -2.0x | XXX | -3.3x | XXX | XXX | XXX |
| EV/Gross Profit | 2.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.5x | XXX | -4.5x | XXX | XXX | XXX |
| EV/FCF | -3.6x | XXX | -57.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGossamer Bio's last 12 month revenue growth is -54%
Gossamer Bio's revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $1.2M for the same period.
Gossamer Bio's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Gossamer Bio's rule of X is -255% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Gossamer Bio and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -54% | XXX | -35% | XXX | XXX | XXX |
| EBITDA Margin | -119% | XXX | -35% | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | -89% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -255% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 121% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 152% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Gossamer Bio acquired XXX companies to date.
Last acquisition by Gossamer Bio was XXXXXXXX, XXXXX XXXXX XXXXXX . Gossamer Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Gossamer Bio founded? | Gossamer Bio was founded in 2015. |
| Where is Gossamer Bio headquartered? | Gossamer Bio is headquartered in United States of America. |
| How many employees does Gossamer Bio have? | As of today, Gossamer Bio has 145 employees. |
| Who is the CEO of Gossamer Bio? | Gossamer Bio's CEO is Mr. Faheem Hasnain. |
| Is Gossamer Bio publicy listed? | Yes, Gossamer Bio is a public company listed on NAS. |
| What is the stock symbol of Gossamer Bio? | Gossamer Bio trades under GOSS ticker. |
| When did Gossamer Bio go public? | Gossamer Bio went public in 2019. |
| Who are competitors of Gossamer Bio? | Similar companies to Gossamer Bio include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Gossamer Bio? | Gossamer Bio's current market cap is $253M |
| What is the current revenue of Gossamer Bio? | Gossamer Bio's last 12 months revenue is $78.3M. |
| What is the current revenue growth of Gossamer Bio? | Gossamer Bio revenue growth (NTM/LTM) is -54%. |
| What is the current EV/Revenue multiple of Gossamer Bio? | Current revenue multiple of Gossamer Bio is 2.5x. |
| Is Gossamer Bio profitable? | Yes, Gossamer Bio is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Gossamer Bio? | Gossamer Bio's last 12 months EBITDA is -$92.8M. |
| What is Gossamer Bio's EBITDA margin? | Gossamer Bio's last 12 months EBITDA margin is -119%. |
| What is the current EV/EBITDA multiple of Gossamer Bio? | Current EBITDA multiple of Gossamer Bio is -2.1x. |
| What is the current FCF of Gossamer Bio? | Gossamer Bio's last 12 months FCF is -$55.6M. |
| What is Gossamer Bio's FCF margin? | Gossamer Bio's last 12 months FCF margin is -71%. |
| What is the current EV/FCF multiple of Gossamer Bio? | Current FCF multiple of Gossamer Bio is -3.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
